Alto Neuroscience, Inc.

    • Market Cap $NaN
    • Debt $NaN
    • Cash $NaN
    • EV $NaN
    • FCF $NaN

    Earnings

    loading chart...

    Sales & Net Margins

    loading chart...

    Assets & ROA

    loading chart...

    Stockholders Equity & ROE

    loading chart...
    Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients' brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates.

    SEC Filings

    Direct access to Alto Neuroscience, Inc. (ANRO) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

    • 2024
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-Q Mar 31
    • 2023
      • 10-K Dec 31

    Sector Comparison

    How does Alto Neuroscience, Inc. compare to its competitors?

    Loading chart...

    Alto Neuroscience, Inc. Discounted Cash Flow

    Fully customizable DCF calculator online for Alto Neuroscience, Inc..

    0
    012345678910TV
    fcf$0$0$0$0$0$0$0$0$0$0$0$0
    DCF$0$0$0$0$0$0$0$0$0$0$0
    Value$0

    Competitiveness and MOAT

    High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

    YearsTTM
    Net Margins-
    ROA-
    ROE-

    Safety and Stability

    Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

    YearsTTM
    Debt over FCF-
    Debt over Equity-
    Growth Stability-

    Growth

    Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

    YearsCAGR 5Y
    Revenue YoY growth-
    Earnings YoY growth-
    Equity YoY growth-
    FCF YoY growth-